Open AccessGlycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma
Author(s) -
Valter Donadon,
Massimiliano Balbi,
Francesca Valent,
Angelo Avogaro
Publication year - 2010
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v16.i24.3025
Subject(s) - medicine , metformin , hepatocellular carcinoma , glycated hemoglobin , gastroenterology , cirrhosis , glycemic , diabetes mellitus , type 2 diabetes mellitus , type 2 diabetes , case control study , insulin , endocrinology
To evaluate the relationship between glycemic control [assessed by glycated hemoglobin (HbA1c)], antidiabetic therapies and the risk of hepatocellular carcinoma (HCC).